nach oben

Erschienen in:

01.08.2012 | Original Article

A brain-derived neurotrophic factor polymorphism Val66Met identifies fibromyalgia syndrome subgroup with higher body mass index and C-reactive protein

Erschienen in: Rheumatology International | Ausgabe 8/2012

Einloggen, um Zugang zu erhalten

Abstract

A common single nucleotide polymorphism (SNP) in the gene of brain-derived neurotrophic factor (BDNF) results from a substitution at position 66 from valine (Val) to methionine (Met) and may predispose to human neuropsychiatric disorders. We proposed to determine whether these BDNF gene SNPs were associated with fibromyalgia syndrome (FMS) and/or any of its typical phenotypes. Patients with FMS (N = 95) and healthy normal controls (HNC, N = 58) were studied. Serum high-sensitivity C-reactive protein (hsCRP) levels were measured using an enzyme-linked immunosorbent assay (ELISA). The BDNF SNPs were determined using polymerase chain reaction-restriction fragment length polymorphism (PCR–RFLP).The BDNF SNP distribution was 65 (68%) Val/Val, 28 (30%) Val/Met, and 2 (2%) Met/Met for FMS and 40 (69%), 17(29%), and 1 (2%) for HNC, respectively. The serum high-sensitivity C-reactive protein (hsCRP)and body mass index (BMI) in FMS were higher than in HNC. The FMS with BDNF Val66Val had significantly higher mean BMI (P = 0.0001) and hsCRP (P = 0.02) than did FMS carrying the Val66Met genotype. This pattern was not found in HNC. Phenotypic measures of subjective pain, pain threshold, depression, or insomnia did not relate to either of the BDNF SNPs in FMS. The relative distribution BDNF SNPs did not differ between FMS and HNC. The BDNF Val66Met polymorphism is not selective for FMS. The BDNF Val66Val SNP identifies a subgroup of FMS with elevated hsCRP and higher BMI. This is the first study to associate a BDNF polymorphism with a FMS subgroup phenotype.

Wolfe F, Smythe HA, Yunus MB et al (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 33:160–172PubMedCrossRef

Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L (1995) The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38:19–28PubMedCrossRef

Staud R (2007) Pathogenesis of chronic muscle pain. Best Pract Res Clin Rheumatol 21(3):581–589PubMedCrossRef

Abeles AM, Pillinger MH, Solitar BM, Abeles M (2007) Narrative review: the pathophysiology of fibromyalgia. Ann Inter Med 146:726–734

Russell IJ, Larson AA (2009) Neurophysiopathogenesis of fibromyalgia syndrome: a unified hypothesis. Rheum Dis Clin North Am 35(2):421–435PubMedCrossRef

Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, Lopez Y, MacKillip F (1994) Elevated cerebrospinal levels of substance P in patients fibromyalgia syndrome. Arthritis Rheum 37:1593–1601PubMedCrossRef

Giovengo SL, Russell IJ, Larson AA (1999) Increased concentrations of nerve growth factor [NGF] in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 26:1564–1569PubMed

Ozgocmen S, Ozyurt H, Sogut S, Akyol O (2006) Current concepts in the pathophysiology of fibromyalgia: the potential role of oxidative stress and nitric oxide. Rheumatol Int 26:585–597PubMedCrossRef

Maes M, Libbrecht I, Hunsel FV, Lin AH, Clerck LD, Stevens W, Kenis G, Jongh R, Bosmans E, Neels H (1999) The immune-inflammatory pathophysiology of fibromyalgia: increased serum soluble gp130, the common signal transducer protein of various neurothrophic cytokines. Psychoneuroendocrinology 24:371–383PubMedCrossRef

10.

Staud R, Smitherman ML (2002) Peripheral and central sensitization in fibromyalgia: pathogenetic role. Curr Pain Headache Rep 6(4):259–266PubMedCrossRef

11.

Banic B, Petersen-Felix S, Andersen OK, Radanov BP, Villiger PM, Arendt-Nielsen L, Curatolo M (2004) Evidence for spinal cord hypersensitivity in chronic pain after whiplash injury and in fibromyalgia. Pain 107(1–2):7–15PubMedCrossRef

12.

Stahl SM (2009) Fibromyalgia–pathways and neurotransmitters. Hum Psychopharmacol 24(Suppl 1):S11–S17PubMedCrossRef

13.

Russell IJ (1998) Advances in fibromyalgia: possible role for central neurochemicals. Am J Med Sci1315(6):377–384

14.

Lipsky RH, Marini AM (2007) Brain-derived neurotrophic factor in neuronal survival and behavior-related plasticity. Ann N Y Acad Sci 1122:130–143PubMedCrossRef

15.

Hu Y, Russek SJ (2008) BDNF and the diseased nervous system: a delicate balance between adaptive and pathological processes of gene regulation. J Neurochem 105(1):1–17PubMedCrossRef

16.

Ying SW, Futter M, Rosenblum K, Webber MJ, Hunt SP, Bliss TV, Bramham CR (2002) Brain-derived neurotrophic factor induces long-term potentiation in intact adult hippocampus: requirement for ERK activation coupled to CREB and upregulation of Arc synthesis. J Neurosci 22(5):1532–1540PubMed

17.

Soulé J, Messaoudi E, Bramham CR (2006) Brain-derived neurotrophic factor and control of synaptic consolidation in the adult brain. Biochem Soc Trans 34(Pt 4):600–604PubMed

18.

Russo-Neustadt AA, Chen MJ (2005) Brain-derived neurotrophic factor and antidepressant activity. Curr Pharm Des 11(12):1495–1510PubMedCrossRef

19.

Yuluğ B, Ozan E, Gönül AS, Kilic E (2009) Brain-derived neurotrophic factor, stress and depression: a minireview. Brain Res Bull 78(6):267–269PubMedCrossRef

20.

Rybakowski JK (2008) BDNF gene: functional Val66Met polymorphism in mood disorders and schizophrenia. Pharmacogenomics 9(11):1589–1593PubMedCrossRef

21.

Licinio J, Dong C, Wong ML (2009) Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch Gen Psychiatry 66(5):488–497PubMedCrossRef

22.

Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, Walker DJ, Chappell AS, Arnold LM (2008) Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 136(3):432–444PubMedCrossRef

23.

Tsai SJ, Cheng CY, Yu YW, Chen TJ, Hong CJ (2003) Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet B Neuropsychiatr Genet 123B(1):19–22PubMedCrossRef

24.

Matsuo K, Walss-Bass C, Nery FG, Nicoletti MA, Hatch JP, Frey BN, Monkul ES, Zunta-Soares GB, Bowden CL, Escamilla MA, Soares JC (2009) Neuronal correlates of brain-derived neurotrophic factor Val66Met polymorphism and morphometric abnormalities in bipolar disorder. Neuropsychopharmacology 34(8):1904–1913PubMedCrossRef

25.

Han JC, Liu QR, Jones M, Levinn RL, Menzie CM, Jefferson-George KS, Adler-Wailes DC, Sanford EL, Lacbawan FL, Uhl GR, Rennert OM, Yanovski JA (2008) Brain-derived neurotrophic factor and obesity in the WAGR syndrome. N Engl J Med 359(9):918–927PubMedCrossRef

26.

Bondy B, Spaeth M, Offenbaecher M et al (1999) The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis 6(5):433–439PubMedCrossRef

27.

Vargas-Alarcón G, Fragoso JM, Cruz-Robles D et al (2007) Catechol-O-methyltransferase gene haplotypes in Mexican and Spanish patients with fibromyalgia. Arthritis Res Ther 9(5):R110PubMedCrossRef

28.

Buskila D, Cohen H, Neumann L, Ebstein RP (2004) An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatr 9(8):730–741CrossRef

29.

Sen S, Nesse RM, Stoltenberg SF, Li S, Gleiberman L, Chakravarti A, Weder AB, Burmeister M (2003) A BDNF coding variant is associated with the NEO personality inventory domain neuroticism, a risk factor for depression. Neuropsychopharmacology 28(2):397–401PubMedCrossRef

30.

Russell IJ, Vaeroy H, Javors M, Nyberg F (1992) Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 35(5):550–556PubMedCrossRef

31.

Vaerøy H, Helle R, Førre O, Kåss E, Terenius L (1988) Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 32(1):21–26PubMedCrossRef

32.

Garcia C, Chen MJ, Garza AA, Cotman CW, Russo-Neustadt A (2003) The influence of specific noradrenergic and serotonergic lesions on the expression of hippocampal brain-derived neurotrophic factor transcripts following voluntary physical activity. Neuroscience 119(3):721–732PubMedCrossRef

33.

Mick E, Wozniak J, Wilens TE, Biederman J, Faraone SV (2009) Family-based association study of the BDNF, COMT and serotonin transporter genes and DSM-IV bipolar-I disorder in children. BMC Psychiatr 9:2CrossRef

34.

Williams SN, Undieh AS (2009) Dopamine D1-like receptor activation induces brain-derived neurotrophic factor protein expression. Neuroreport 20(6):606–610PubMedCrossRef

35.

Wood PB, Glabus MF, Simpson R, Patterson JC 2nd (2009) Changes in gray matter density in fibromyalgia: correlation with dopamine metabolism. J Pain 10(6):609–618PubMedCrossRef

36.

Taylor WD, Züchner S, McQuoid DR, Steffens DC, Blazer DG, Krishnan KR (2008) Social support in older individuals: the role of the BDNF Val66Met polymorphism. Am J Med Genet B Neuropsychiatr Genet 147B(7):1205–1212PubMedCrossRef

37.

Wray NR, James MR, Handoko HY, Dumenil T, Lind PA, Montgomery GW, Martin NG (2008) Association study of candidate variants from brain-derived neurotrophic factor and dystrobrevin-binding protein 1 with neuroticism, anxiety, and depression. Psychiatr Genet 18(5):219–225PubMedCrossRef

38.

Laske C, Stransky E, Eschweiler GW, Klein R, Wittorf A, Leyhe T, Richartz E, Köhler N, Bartels M, Buchkremer G, Schott K (2007) Increased BDNF serum concentration in fibromyalgia with or without depression or antidepressants. J Psychiatr Res 41(7):600–605PubMedCrossRef

39.

Shugart YY, Chen L, Day IN, Lewis SJ, Timpson NJ, Yuan W, Abdollahi MR, Ring SM, Ebrahim S, Golding J, Lawlor DA, Davey-Smith G (2009) Two British women studies replicated the association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) and BMI. Eur J Hum Genet 17(8):1050–1055PubMedCrossRef

40.

Jiang H, Wang R, Liu Y, Zhang Y, Chen ZY (2009) BDNF Val66Met polymorphism is associated with unstable angina. Clin Chim Acta 400(1–2):3–7PubMedCrossRef

41.

Neumann L, Lerner E, Glazer Y, Bolotin A, Shefer A, Buskila D (2008) A cross-sectional study of the relationship between body mass index and clinical characteristics, tenderness measures, quality of life, and physical functioning in fibromyalgia patients. Clin Rheumatol 27(12):1543–1547PubMedCrossRef

42.

Yunus MB, Arslan S, Aldag JC (2002) Relationship between body mass index and fibromyalgia features.Scand J Rheumatol 31(1):27–31

43.

Kraus VB, Stabler TV, Luta G, Renner JB, Dragomir AD, Jordan JM (2007) Interpretation of serum C-reactive protein (CRP) levels for cardiovascular disease risk is complicated by race, pulmonary disease, body mass index, gender, and osteoarthritis. Osteoarthritis Cartilage 15(8):966–971PubMedCrossRef

44.

Lui MM, Lam JC, Mak HK, Xu A, Ooi C, Lam DC, Mak JC, Khong PL, Ip MS (2009) C-reactive protein is associated with obstructive sleep apnea independent of visceral obesity. Chest 135(4):950–956PubMedCrossRef

45.

Unger TJ, Calderon GA, Bradley LC, Sena-Esteves M, Rios M (2007) Selective deletion of Bdnf in the ventromedial and dorsomedial hypothalamus of adult mice results in hyperphagic behavior and obesity. J Neurosci 27:14265–14274PubMedCrossRef

46.

Rios M, Fan G, Fekete C et al (2001) Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. Mol Endocrinol 15:1748–1757PubMedCrossRef

47.

Mirowska-Guzel D, Mach A, Gromadzka G, Czlonkowski A, Czlonkowska A (2008) BDNF A196G and C270T gene polymorphisms and susceptibility to multiple sclerosis in the Polish population. Gender differences. J Neuroimmunol 193(1–2):170–172PubMedCrossRef

48.

Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112(2):257–269PubMedCrossRef

49.

Chen ZY, Patel PD, Sant G, Meng CX, Teng KK, Hempstead BL, Lee FS (2004) Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci 24(18):4401–4411PubMedCrossRef

Titel: A brain-derived neurotrophic factor polymorphism Val66Met identifies fibromyalgia syndrome subgroup with higher body mass index and C-reactive protein
Publikationsdatum: 01.08.2012
Erschienen in: Rheumatology International / Ausgabe 8/2012
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-011-1990-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2012

An unusual pediatric case with neurofibromatosis and systemic lupus erythematosus

The relationship between plasma homocysteine level and different treatment modalities in patients with ankylosing spondylitis

Sonographic assessment of carpal tunnel syndrome in rheumatoid arthritis: prevalence and correlation with disease activity

Negative serology: could exclude the diagnosis of brucellosis?

Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4